4 citations
,
August 2021 in “Annals of Translational Medicine” In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.
April 2018 in “The Journal of Urology” This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.
March 2026 in “Journal of Multidisciplinary Applied Natural Science” This study reported that Cosmos caudatus extract alone may therapeutically modulate the AR–FGF-2 axis in a BPH rat model, comparable to finasteride, but combining them disrupted pathway regulation, increasing TGF-β levels.
May 2023 in “MQRInvestigar” In this case study, a 3-year-old German Shepherd treated for an enlarged prostate with medication and surgery showed a significant prostate size reduction by 93.9% over 138 days, ruling out neoplastic processes.
2 citations
,
January 2009 in “The Journal of Internal Korean Medicine” In this study, Scutellaria baicalensis was observed to reduce tissue damage and inhibit 5α-reductase expression in a rat model of benign prostatic hyperplasia.